

Journal of Visualized Experiments

qPCR-BASED ANALYSES OF INTESTINAL MICROBIOTA AFTER ORAL ANTIBIOTIC TREATMENT OF MICE

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58481R1
Full Title:	qPCR-BASED ANALYSES OF INTESTINAL MICROBIOTA AFTER ORAL ANTIBIOTIC TREATMENT OF MICE
Keywords:	Intestinal microbiota, antibiotics, 16S rRNA, faecal bacteria, qPCR, faecal sample collection
Corresponding Author:	Patricia Barral King's College London London, London UNITED KINGDOM
Corresponding Author's Institution:	King's College London
Corresponding Author E-Mail:	patricia.barral@kcl.ac.uk
Order of Authors:	Patricia Barral Rebeca Jimeno Phillip M. Brailey
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Francis Crick Institute; 1 Midland Road, NW1 1AT London

TITLE:**Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment****AUTHORS AND AFFILIATIONS:**

Rebeca Jimeno^{1,2}, Phillip M. Brailey^{1,2}, Patricia Barral^{1,2}

¹The Peter Gorer Department of Immunobiology. King's College London. London, UK

²The Francis Crick Institute, London, UK

Corresponding author:

Patricia Barral

Tel: +44 (0)2037963358

E-mail: patricia.barral@kcl.ac.uk

Email addresses of co-authors:

Rebeca Jimeno: rebeca.jimeno_lumeras@kcl.ac.uk

Phillip Brailey: phillip.brailey@kcl.ac.uk

KEYWORDS:

Intestinal microbiota, antibiotics, 16S rRNA, fecal bacteria, qPCR, fecal sample collection

SUMMARY:

Here we provide detailed protocols for the oral administration of antibiotics to mice, collection of fecal samples, DNA extraction and quantification of fecal bacteria by qPCR.

ABSTRACT:

The gut microbiota has a central influence on human health. Microbial dysbiosis is associated with many common immunopathologies such as inflammatory bowel disease, asthma and arthritis. Thus, understanding the mechanisms underlying microbiota-immune system crosstalk is of crucial importance. Antibiotic administration, while aiding pathogen clearance, also induces drastic changes in the size and composition of intestinal bacterial communities which can have an impact on human health. Antibiotic treatment in mice recapitulates the impact and long-term changes in human microbiota from antibiotic treated patients, and enables investigation of the mechanistic links between changes in microbial communities and immune cell function. While several methods for antibiotic treatment of mice have been described, some of them induce severe dehydration and weight-loss complicating the interpretation of the data. Here, we provide two protocols for oral antibiotic administration which can be used for long-term treatment of mice without inducing major weight-loss. These protocols make use of a combination of antibiotics that target both Gram-positive and Gram-negative bacteria and can be provided either *ad libitum* in the drinking water or by oral gavage. Moreover, we describe a method for the quantification of microbial density in fecal samples by qPCR which can be used to validate the efficacy of the antibiotic treatment. The combination of these approaches provides a reliable

methodology for the manipulation of the intestinal microbiota and the study of the effects of antibiotic treatment in mice.

INTRODUCTION:

The mammalian gastrointestinal mucosa is a unique environment colonized by a highly complex mixture of microorganisms that establish a mutualistic relationship with the host. The defense system of the intestinal mucosa comprises an epithelial layer and a plethora of immune cells that restrict commensals within the intestine while preserving their number and diversity. Conversely, commensal organisms are required for the development of a fully functional immune system. While interactions between host and commensal bacteria are normally beneficial, it is becoming increasingly clear that dysregulated immune system-microbiota crosstalk can favor the development of chronic inflammatory diseases, such as inflammatory bowel disease, arthritis or asthma^{1,2}.

The gut microbiota can be altered by various factors, but perhaps the most drastic changes are induced by antibiotic treatment that severely alters both the size and composition of bacterial communities^{3,4}. While the benefits of antibiotics to treat infections are unquestionable, the microbiota changes induced by antibiotic exposure in humans can also modify immune defenses which can lead to detrimental effects on health. For instance, antibiotic treatment in humans has been linked to an increased risk of *Clostridium difficile*-induced diarrhea, asthma and certain types of cancer³. Antibiotic treatment in mice recapitulates the impact and long-term alterations found in gut communities of antibiotic-treated patients, and has enabled investigation of the mechanistic links between changes in microbial communities and immune cell function. However, several reports have shown that administration of antibiotics on the drinking water *ad libitum* results in very noticeable weight loss as mice refrain from drinking water, presumably due to its foul taste^{5,6}. Thus, in these models the severe dehydration concomitant to oral antibiotic administration may complicate the interpretation of experiments aiming to identify the effect of antibiotic treatment in immune cell function.

Several approaches can be used to explore the size and composition of microbial communities in the intestinal compartment⁷. Next generation sequencing technologies have provided invaluable data on this matter⁸, however these methods are relatively expensive and require expert bioinformatic analyses for interpretation of the data. On the other hand, traditional microbiological culture methods allow detection of the bacterial species, but they have low sensitivity and a large fraction of commensal bacteria (particularly anaerobes) are very difficult or impossible to cultivate with currently available methods⁸. Quantitative polymerase chain reaction (qPCR) techniques are being used increasingly for quantification and identification of fecal bacterial species, as they provide a fast and reliable culture-independent measure of total microbial load. Accordingly, qPCR methods have proved useful to study changes in the microbiota associated with age or with progression of several diseases including inflammatory bowel disease^{9,10}. In line with this, qPCR methods provide a fast and cost-effective approach to validate the effect of various treatments (including antibiotics) in fecal bacterial loads and microbiota composition¹⁰⁻¹².

Here, we present a detailed step-by-step account of two distinct protocols for oral antibiotic administration to mice, fecal sample collection, DNA extraction, preparation of standards and quantification of bacteria in fecal samples by qPCR. These protocols provide a reliable method to manipulate the intestinal microbiota in mice and to study of the effects of antibiotic treatment in intestinal homeostasis and disease.

PROTOCOL:

Experiments described here were performed using 6-8 weeks old wild-type (C57BL6/J) mice maintained in a specific pathogen free (SPF) facility. All animal experiments were approved by the King's College London and the Francis Crick Institute Animal Welfare and Ethical Review Body and the United Kingdom Home Office. Prior to beginning any animal procedure, ensure that the appropriate permissions are obtained through the local institution/organization.

1. Administration of Antibiotics

Note: Two alternative methods for antibiotic treatment are provided: oral gavage (step 1.1) and administration of antibiotics via drinking water (step 1.2).

1.1. Oral gavage

1.1.1. Prepare stocks of individual antibiotics by dissolving them in autoclaved water at the following concentrations: Ampicillin at 100 mg/mL, Gentamicin at 100 mg/mL, Neomycin at 100 mg/mL, Metronidazole at 10 mg/mL and Vancomycin at 100 mg/mL. Filter sterilize using a 0.45 µm filter. Aliquot and store at -20 °C.

1.1.2. Prepare a cocktail of antibiotics by mixing the stocks prepared above. For a volume of 1 mL mix 50 µL of Ampicillin (5 mg/mL final), 50 µL of Gentamicin (5 mg/mL final), 50 µL of Neomycin (5 mg/mL final), 500 µL of Metronidazole (5 mg/mL final), 25 µL of Vancomycin (2.5 mg/mL final) and 325 µL of water. Prepare the cocktail fresh before use.

1.1.3. Fix an appropriate gauge gavage needle (20 G for 15–20 g mice) onto a sterile 1 mL syringe and load the antibiotic mix while eliminating any bubbles.

1.1.4. Gavage mice with 200 µL of antibiotic mix.

1.1.4.1. Grab the skin over the mouse shoulder firmly, stretch the head and neck to straighten the esophagus. Direct the ball-tip of the feeding needle along the roof of the mouth and toward the back of the pharynx. Then, gently pass it down into the esophagus and inject the 200 µL solution.

1.1.5. Administer the antibiotic cocktail once daily for the duration of the experiment.

1.2. Antibiotics in the Drinking Water

CAUTION: Carefully monitor mouse weight daily for the first two weeks of antibiotic administration in the drinking water.

1.2.1. Prepare a cocktail of antibiotics by dissolving the following in 1 L of autoclaved water: 1 g of Ampicillin (1 g/L final), 1 g of Neomycin (1 g/L final), 1 g of Metronidazole (1 g/L final), 0.5 g of Vancomycin (0.5 g/L final) and 8 sachets (0.75 g each) of artificial sweetener (60 g/L final). Shake until dissolved. Store at 4 °C.

Note: Sweetener is added to hide the flavor of antibiotics and prevent mice dehydration. While several sweetener brands may work, the final concentration required may be different for each specific brand.

1.2.2. Fill the antibiotic cocktail into a water bottle (~100 mL/bottle) and place the bottle on a mouse cage.

Note: Use brown bottles or cover the bottles with foil to protect antibiotics from light.

1.2.3. Replace the antibiotic cocktail with fresh stock twice a week for the duration of the experiment.

2. Collection of Fecal Samples from Stool, Ileum Content and Ileum Wall

2.1. Weigh and label 2 mL autoclaved tubes for sample collection.

2.2. For collection of fresh stool samples, place each mouse in a restrainer and collect fecal pellets directly from the anus in a collection tube.

Note: Samples can also be obtained by placing mice in a clean autoclaved cage, and collecting stool samples with clean sterilized forceps.

2.3. Euthanize the mice with CO₂ asphyxiation followed by cervical dislocation.

2.4. Lay a mouse carcass with the abdomen fully exposed and spray the abdominal area with 70% ethanol.

2.5. Using sterilized forceps and scissors, make a transverse incision in the abdomen to expose the peritoneum without damaging any internal tissues. Lift the peritoneum and make an incision to expose the intestines.

2.6. Remove the intestines (from colon to stomach) with the forceps and scissors and place it in a sterile Petri dish.

2.7. Carefully use forceps to tease the small intestine (SI) away from the mesenteric arteries and fat. Extend the intestine and place it on a clean lab wipe.

2.8. With a ruler, measure and cut 4 cm of the distal ileum of the SI (the closest part to the cecum). Cut and discard the 1 cm of intestine proximal to the cecum. There will be a 3 cm portion of ileum left which will be used to collect intestinal bacteria.

2.9. Hold the ileum portion (3 cm) over a 2 mL sterile tube. Collect the intestinal content by directly extruding the intestine and collecting the sample in the tube. This sample will have bacteria from the ileum content.

2.10. Prepare a 20 mL syringe with cold phosphate buffered saline (PBS) and flush the ileum portion (discard the flow-through).

2.11. Place the ileum portion on a clean In wipe/napkin and open it longitudinally with scissors.

2.12. Scrape the inside of the ileum wall with a scalpel.

2.13. Collect any bacteria on the scalpel by washing the scalpel with 1 mL of PBS over a clean centrifuge tube. Spin at $8000 \times g$ for 5 min to pellet the bacteria and discard the supernatant. This sample will contain bacteria from the ileum wall.

Note: Fecal samples from stool, ileum content and wall can be frozen and stored at -80°C until use.

2.14. Weigh the tubes containing the samples from stool and ileum content, and subtract the weight from the empty tubes (from step 2.1) to obtain the fecal weight in each sample.

2.15. Extract bacterial DNA from stool, ileum content and ileum wall samples using commercially available kits. Store DNA samples at -20°C until use.

3. Quantification of Intestinal Microbiota by qPCR

Note: This procedure includes the generation of a standard (step 3.1) and the method for qPCR set-up for standard and fecal samples (step 3.2)

3.1. Generation of a standard for qPCR

3.1.1. Use polymerase chain reaction (PCR) to amplify the 16S rRNA gene from the genomic DNA extracted from a bacterial culture using the reagents¹³ and PCR conditions detailed in **Table 1**.

3.1.2. Run the PCR product on a 1.5% agarose gel and purify the DNA band using a commercially available DNA extraction kit.

3.1.3. Ligate the purified DNA fragment using a cloning kit (see the **Table of Materials**, use a vector containing antibiotic resistance markers and β -galactosidase (*LacZ*) gene fusion for

blue/white colony selection) and transform DH10 competent *E. coli* following the manufacturer's instructions. Plate transformation onto Ampicillin (100 µg/mL), X-gal (20 µg/mL) Luria Bertani (LB) agar plates (10 g/L Tryptone, 5 g/L Yeast Extract, 10 g/L NaCl, 15 g/L Agar). Incubate overnight (O/N) at 37 °C.

3.1.4. Select a single positive (white) colony from the plate. Inoculate it in 5 mL LB broth containing 100 µg/mL Ampicillin and incubate O/N at 37 °C, shaking at 250 rpm.

3.1.5. From the O/N culture, isolate and purify the plasmid using a commercial miniprep kit according to manufacturer's instructions.

Note: It is important to sequence the plasmid insert at this stage, to ensure that the plasmid contains only one copy of the 16S rRNA gene and to determine its length in base-pairs (bp).

3.1.6. Linearize the plasmid with a restriction enzyme which cuts the plasmid only once.

3.1.7. Purify the linearized plasmid using a commercially available kit.

3.1.8. Determine the concentration of the plasmid by measuring absorbance at 260 nm using a spectrophotometer.

3.1.9. Calculate the number of plasmid copies/µL of sample using the following formula¹⁴:

$$\text{number of copies} = (\text{amount} * 6.022 \times 10^{23}) / (\text{length} * 1 \times 10^9 * 650)$$

where *amount* is the DNA concentration obtained in step 3.1.8 (in ng/µL); and *length* is the total length of the plasmid (with the insert) in bp. The *number of copies* will be obtained as copies/µL.

Note: There are online tools based on the above formula that enable easy calculation of the number of plasmid copies.

3.1.10. Aliquot and store the standard as needed at -20 °C until use.

3.2. qPCR Set-up for Standard and Fecal Samples

3.2.1. Thaw the qPCR standard (from step 3.1.10), fecal samples DNA (from step 2.15) and qPCR reagents (from a commercially available kit) on ice.

Note: qPCR reagents used in this example include the SYBR Green qPCR reaction mix and forward and reverse primers (Table 2).

3.2.2. Dilute the standard in sterile DNA-free water in a range from 10⁷ to 10² copies/µL (e.g., 1/5 serial dilutions from 10⁷ to 6.4 x 10² copies/µL). Dilute fecal sample DNA to 1/2, 1/5, 1/10.

3.2.3. Make a master mix reaction for the total number of reactions plus 1 (Table 2).

3.2.4. Mix 30 μ L of the master mix and 5 μ L of template (standard, sample or water for negative control)

3.2.5. Add 10 μ L of this mix to each well in a 384-well optical qPCR plate. Perform each reaction in triplicate.

3.2.6. Seal the qPCR place, centrifuge briefly and load the plate on the qPCR machine programmed with the following cycling conditions: 95 °C for 20 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.

3.2.7. Obtain C_T values for standard and samples.

3.2.8. Generate a standard curve by plotting the C_T values for the standards versus the logarithm of the copy number of the plasmid (as calculated in step 3.1.9). Perform lineal regression of the standard curve.

3.2.9. Calculate the 16S rDNA copy numbers for fecal samples by interpolating C_T values (obtained in step 3.2.2) in the standard curve.

Note: 16S rDNA copy numbers for each sample should be corrected considering the dilution factor of the sample (as prepared in step 3.2.2), the final volume nucleic acids that were eluted (in step 2.15) and the quantity of fecal sample (calculated in step 2.14) to obtain gene copies per gram of feces.

REPRESENTATIVE RESULTS:

Here we provide two alternative protocols for oral antibiotic treatment of mice. **Figure 1** shows percentage of body-weight (related to original base line weight for each animal) in mice treated with antibiotics either by oral gavage (red) or in the drinking water (blue) for 10 consecutive days. No noticeable weight-loss is found in mice that receive antibiotics by oral gavage. However, when mice are treated with antibiotics *ad libitum* in the drinking water, they lose weight (~10%) within the first few days of antibiotic administration, but recover normal weight gain thereafter (**Figure 1**). Nonetheless, around 5–10% of mice receiving antibiotics in the drinking water can reach >20% weight loss within the first week of treatment, in which case they are euthanized.

The quantification of bacteria in fecal samples requires the use of an adequate standard curve which is obtained by plotting the log of copy number for the standard (as calculated in step 3.2.2) versus the C_T values obtained from qPCR (step 3.2.7). **Figure 2A** shows a representative example from a standard curve which meets the standard curve performance criteria with a R^2 value of 0.99827, a slope of -3.09 and a efficiency $((-1 + 10^{(-1/\text{slope})}) \times 100)$ of 110%. R^2 values of 0.99 and PCR efficiencies within the range of 90 to 110% are preferred. Within the linear range, the regression analysis equation enables quantification of the 16S rDNA abundance within the fecal samples. **Figure 2B** shows the number of 16S rDNA copies in fecal stool, SI content and SI wall. In

Figure 2B data are shown as 16S rDNA copies/g of fecal sample for fecal stool and SI content. For SI wall, data are presented as total number of 16S rDNA copies obtained from bacteria recovered from the 3 cm of SI wall (as the quantity of starting material is too small to obtain a precise weight).

To evaluate the effect of antibiotics on the density of bacteria in fecal samples, mice were treated with antibiotics by oral gavage daily for 10 days (days 1 to 10) and stool samples were collected before (day 0), at different time-points during antibiotic treatment (days 5 and 10), and 7 days after stopping antibiotic administration (day 17; **Figure 3A**). As shown in **Figure 3B**, antibiotic treatment induces a strong decrease in the number of 16S rDNA copies/g of feces detected at days 5 and 10, while the density of bacteria in the feces recovered to normal levels (comparable to pre-treatment) 1 week after antibiotic administration was stopped (day 17).

FIGURE AND TABLE LEGENDS:

Figure 1. Administration of antibiotics. Mice received antibiotics either by oral gavage (red) or in the drinking water (blue) for 10 consecutive days. Plot shows weights of mice throughout the duration of the experiments relative to original weight before antibiotic administration (day 0). Data are shown as mean \pm SEM.

Figure 2. 16S rRNA gene qPCR amplification of standards and fecal samples. (A) Linear regression of standard curve with standard curve descriptors. (B) Calculation of gene abundances from fecal samples. Data are shown as mean \pm SEM.

Figure 3. Fecal bacteria during antibiotic treatment. (A) Schematic of the schedule for antibiotic administration by oral gavage (Ab) and sample collection as depicted with *. (B) 16S rDNA copies per gram of feces in stool samples from mice collected at the indicated days. Data are shown as mean \pm SEM.

Table 1. PCR reagents and conditions. This table provides the reagents and PCR cycling conditions to amplify 16S rRNA gene from bacterial culture for generation of a standard to use in the qPCR assays. Primer sequences were originally published by Kruglov *et al.*¹³.

Table 2. qPCR master mix. The volumes shown (final volume 35 μ L) are for a single sample to be run on triplicate (10 μ L each) on a 384-well qPCR plate (accounting for 5 μ L extra for pipetting error). The amount may be scaled up according to the number of samples to be analyzed.

DISCUSSION:

Here we provide experimental protocols for oral administration of antibiotics to mice and quantification of fecal bacteria by qPCR. The combination of antibiotics used in this protocol (containing ampicillin, gentamicin, neomycin, metronidazole and vancomycin) targets both Gram-positive and Gram-negative bacteria, offering bactericidal activity against a full spectrum of bacteria. Both oral gavage and administration of antibiotics in the drinking water greatly decrease fecal bacterial load^{5,6,12}. Moreover, both treatments have a profound effect on the

phenotype of the mice as they develop several characteristics typical of germ-free mice including reduced spleen size and enlarged cecum. The selection of a particular method for antibiotic administration may possibly depend on the length of the experiment as the oral gavage method requires daily administration of antibiotics, being more labor-intensive and possibly causing more discomfort to the animals in the long-run.

For administration of antibiotics in the drinking water, caution must be taken with the addition of the sweetener to the antibiotic mixture as this is a crucial factor to keep mice from dehydration. Several groups have shown how administration of antibiotics in drinking water (without addition of sweetener) leads to very severe and rapid weight-loss with all mice losing more than 20% of initial body weight within the first few days of the experiment^{5,6}. In our protocol, the use of the saccharine-based sweetener seemed to be sufficient to mask the antibiotic taste in the water and mice lost weight in the first few days after antibiotic administration, but recovered their weights quickly after that (**Figure 1**). Nonetheless, in our experiments 5–10% of mice still reach the human end-point of >20% loss of baseline body weight and needed to be euthanized. We have also tested sucralose-based sweeteners which completely failed to prevent mice dehydration (100% of mice lost >20% of weight) while other authors have published similar failures for aspartame-based sweeteners^{5,6}. Added to this, the age, genetic background and general health status of the mice used for the experiments should be considered, as they may influence weight-loss and animal well-being during antibiotic treatment. Thus, careful monitoring of mice weight and general health status should be performed daily during the first two weeks of oral antibiotic administration.

qPCR methods provide a fast and cost-effective approach for quantification of 16S rRNA in fecal samples. However, some limitations should be considered regarding this technique including: i) the requirement for a reliable high-quality standard; ii) the design and efficiency of the qPCR primers; iii) the fact that microorganisms may have different copy numbers of the 16S rRNA gene, thus gene copies may not directly equal cell counts¹⁵. Nonetheless, qPCR is a robust and sensitive method which enables rapid analysis of fecal samples. This method can be particularly useful to quickly validate the effect of various treatments (including antibiotics) in fecal bacterial loads as detailed here. Moreover, although we provide a protocol for quantification of *total* 16S rRNA, this method can be easily adapted (by designing specific primers¹⁶) to enable identification of individual bacterial taxa, thus providing both quantitative and qualitative information about microbiome size and composition.

In summary, we have provided two protocols for oral antibiotic treatment of mice and a qPCR-based method to quantify antibiotic-induced changes in fecal bacteria. Although these protocols can be further optimized and combined with other approaches according to individual experimental needs, they may serve as quick, cost-effective and reliable tools to manipulate the murine intestinal microbiota and to study of the effects of antibiotic treatment in intestinal homeostasis and disease.

ACKNOWLEDGMENTS:

This work was funded by the UK Medical Research Council (grant to P.B. MR/L008157/1); R.J. was supported by a Marie Curie Intra-European Fellowship (H2020-MSCA-IF-2015-703639); P.M.B. was supported by a studentship from the UK Medical Research Council and King's College London Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. *Cell*. **157** (1), 121-141, (2014).
- 2 Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. *Science*. **336** (6086), 1268-1273, (2012).
- 3 Ubeda, C. & Pamer, E. G. Antibiotics, microbiota, and immune defense. *Trends in Immunology*. **33** (9), 459-466, (2012).
- 4 Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biology*. **6** (11), e280, (2008).
- 5 Reikvam, D. H. *et al.* Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. *PLoS One*. **6** (3), e17996, (2011).
- 6 Hill, D. A. *et al.* Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. *Mucosal Immunology*. **3** (2), 148-158, (2010).
- 7 Fraher, M. H., O'Toole, P. W. & Quigley, E. M. Techniques used to characterize the gut microbiota: a guide for the clinician. *Nature Reviews Gastroenterology & Hepatology*. **9** (6), 312-322, (2012).
- 8 Eckburg, P. B. *et al.* Diversity of the human intestinal microbial flora. *Science*. **308** (5728), 1635-1638, (2005).
- 9 Sokol, H. *et al.* Low counts of *Fecalibacterium prausnitzii* in colitis microbiota. *Inflammatory Bowel Diseases*. **15** (8), 1183-1189, (2009).
- 10 Bartosch, S., Fite, A., Macfarlane, G. T. & McMurdo, M. E. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. *Applied Environmental Microbiology*. **70** (6), 3575-3581, (2004).
- 11 Ubeda, C. *et al.* Vancomycin-resistant *Enterococcus* domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. *Journal of Clinical Investigation*. **120** (12), 4332-4341, (2010).
- 12 Saez de Guinoa, J. *et al.* CD1d-mediated lipid presentation by CD11c(+) cells regulates intestinal homeostasis. *EMBO Journal*. **37** (5), (2018).
- 13 Kruglov, A. A. *et al.* Nonredundant function of soluble LT α 3 produced by innate lymphoid cells in intestinal homeostasis. *Science*. **342** (6163), 1243-1246, (2013).
- 14 Wilhelm, J., Pingoud, A. & Hahn, M. Real-time PCR-based method for the estimation of genome sizes. *Nucleic Acids Research*. **31** (10), e56, (2003).

438 15 Kembel, S. W., Wu, M., Eisen, J. A. & Green, J. L. Incorporating 16S gene copy number
439 information improves estimates of microbial diversity and abundance. *PLoS Computational*
440 *Biology*. **8** (10), e1002743, (2012).

441 16 Yang, Y. W. *et al.* Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time
442 PCR Analysis of Predominant Bacteria in Mouse Feces. *Applied Environmental Microbiology*. **81**
443 (19), 6749-6756, (2015).

444

Figure 1




Figure 2





Figure 3



Reagent	Volume
DNA	8 µL
Buffer 10X	2 µL
dNTPs (10mM)	0.4 µL
Eubacteria - F primer (10 mM)	1 µL
Eubacteria - R primer (10 mM)	1 µL
Taq Polimerase	0.2 µL
H ₂ O	7.4 µL
Total volume	20 µL

Primer sequences	
Eubacteria - F primer	5' ACTCCTACGGGAGGCAGCAGT 3'
Eubacteria - R primer	5' ATTACCGCGGCTGCTGGC 3'

Cycling conditions

Temperature	Time	Cicles
94 °C	5 min	1x
94 °C	30 s	
60 °C	30 s	30x
72 °C	1 min	
72 °C	5 min	1x
4 °C	∞	1x

Reagent	Volume
SYBR Green master mix (2x)	17.5 µL
Eubacteria - F primer (10 mM)	0.7 µL
Eubacteria - R primer (10 mM)	0.7 µL
H ₂ O	11.1 µL

Name of Material/ Equipment

Ampicillin sodium salt
Neomycin trisulfate salt hydrate
Metronidazole
Vancomycin hydrochloride
Gentamicin sulfate salt
Tryptone
Yeast Extract
NaCL
Sweetener Sweet'n Low
X-Gal (5-brom-4-chloro-3-indoyl B-D-galactopyranoside)
Phosphate Buffered Saline
Ultrapure Agarose
RT-PCR grade water
Phusion High-Fidelity DNA Polymerase
Deoxynucleotide (dNTP) Solution Mix
iQ Taq Universal SYBR Green Supermix
TOPO TA cloning™ for sequencing
QIAamp fast DNA Stool mini kit
QIAprep spin Miniprep kit
QIAquick gel extraction kit
Syringe filter 0.45µm
Swann-Morton™ Carbon steel sterile scalpel blades
Syringe (1 ml)
Syringe (20 ml)
1.5ml Crystal clear microcentrifuge tube
2ml Ultra high recovery microcentrifuge tube
Oral dosing needles 20Gx38 mm curved (pk/3)
Sterilin petri dish 50 mm

Absolute qPCR plate seals

MicroAmp™ optical 384-well plate

ViiA7™ 7 real-time PCR system with 384-well block

Spectrophotometer (Nanodrop 1000)

Labnet Prism microcentrifuge

MultiGene Optimax Thermal cycler

Company	Catalog Number	Comments/Description
Sigma-Aldrich (Merck)	A9518	
Sigma-Aldrich (Merck)	N1876	
Sigma-Aldrich (Merck)	M3761	
Sigma-Aldrich (Merck)	V2002	
Sigma-Aldrich (Merck)	G3632	
Sigma-Aldrich (Merck)	T7293	
Sigma-Aldrich (Merck)	Y1625	
Sigma-Aldrich (Merck)	S7653	
Sweet'N Low		Available in the UK from Amazon.co.u
Fisher scientific	10234923	
Thermo Fisher Scientific (Gibco)	10010023	
Thermo Fisher Scientific (Invitrogen)	16500500	
Thermo Fisher Scientific (Invitrogen)	AM9935	
New England BioLabs	M0530	
New England BioLabs	N0447	
Bio-Rad	1725124	with ROX
Thermo Fisher Scientific (Invitrogen)	450030	
Qiagen	51604	
Qiagen	27106	
Qiagen	28704	
Fisher scientific	10460031	
Fisher scientific	11792724	
BD Plastipak	303172	
BD Plastipak	300613	
StarLab	E1415-1500	
StarLab	I1420-2600	
Vet-Tech	DE008A	
Scientific Laboratory Supplies	PET2020	

Thermo Fisher Scientific	AB1170
Thermo Fisher Scientific (Applied Biosystems)	4309849
Thermo Fisher Scientific (Applied Biosystems)	4453536
Thermo Fisher Scientific	ND-1000
Labnet	C2500
Labnet	TC9610

k



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT - UK

Title of Article:

qPCR-based analyses of intestinal microbiote after antibiotic

Author(s):

R. JIMENO, PM BRAILEY, P. BARRAL

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via:

☐

Standard Access

☒

Open Access

Item 2 (check one box):

☒

The Author is NOT a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐

The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution 3.0 Agreement (also known as CC-BY), the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by/3.0/us/legalcode>;

"**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJove Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*;

"**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and

(c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the

ARTICLE AND VIDEO LICENSE AGREEMENT - UK

Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict

shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including,

ARTICLE AND VIDEO LICENSE AGREEMENT – UK

without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or

damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

AUTHOR:

Name:

PATRICIA BARRAL

Department:

PETER GORER DEPT OF IMMUNOLOGY

Institution:

KING'S COLLEGE LONDON

Article Title:

qPCR-BASED ANALYSES OF INTESTINAL MICROBIOTA AFTER ANTIBIOTIC TREATMENT OF MICE

Signature:

[Handwritten Signature]

Date:

16/05/18

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy as a PDF to the JoVE submission site upon manuscript submission (preferred);
- 2) Fax the document to +1.866.381.2236; or
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center Suite 200 / Cambridge, MA 02140

For questions, please email editorial@jove.com or call +1.617.945.9051.

MS # (internal use):

Re: “qPCR-BASED ANALYSES OF INTESTINAL MICROBIOTA AFTER ORAL ANTIBIOTIC TREATMENT OF MICE” by Rebeca Jimeno, Phillip M. Brailey & Patricia Barral (JoVE58481)

Reply to reviewers

We are very grateful for the positive and constructive comments provided by the reviewers and editors and their thoughtful questions. We have reviewed the figures and the manuscript according to their suggestions as detailed below:

Editorial comments:

1. The manuscript has been carefully revised
2. The protocol included in part 3 (DNA extraction) corresponds to the step-by-step protocol from a commercially available kit (Qiagen QIAamp fast DNA Stool mini kit). As this protocol is available in the manufacturer's webpage and in response to comments from reviewer 1 (about unnecessary steps), we have deleted this part of the protocol from the current manuscript. We believe that this simplifies the manuscript making it more accessible to readers. However, if the editor considers that this part provides valuable information for the readers we would be happy to include the text back and modify it as required.
3. CT values don't have a specific unit
4. Figure 3B has been changed
5. Tables have been revised
6. Keywords have been added
7. This has been done
8. This has been done
9. This has been done
10. This has been done
11. Commercial language has been removed from the manuscript
12. This has been included in the manuscript
13. This has been included in the manuscript
14. This has been changed in the manuscript
15. This has been revised
16. This has been revised
17. This has been revised
18. References have been changed

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

Authors described a protocol for analyzing intestinal microbiota using qPCR.

Major Concerns:

Overall concern is that the paper lacks scientific rationale for the method. Purely describe too many boring and unnecessary steps

We appreciate the concerns from reviewer 1 and, as requested, we have simplified the protocol steps to make the manuscript more accessible to readers and the protocol easier to follow (see reply to editorial comments (2) above).

1) *No explanation how qPCR can be used to quantify microbiota.*

The method for quantification of the microbiota requires the generation of a standard curve, and unknown samples (from stool or intestinal lumen) are quantified against the standard curve. The process involved in the quantification of the bacterial samples is detailed in the results section. However, to further clarify this part of the protocol, we have included additional steps in our protocol (steps 3.2.8-3.2.9) specifically explaining the processes used to calculate the number of 16S rDNA copy numbers in the bacterial sample.

2) No explanation of formula used to calculate number of copies. line 271

We have included an appropriate reference (ref 14) for a paper that explains the underlying calculations used to devise the formula included in our manuscript

We have also referred in the manuscript to online tools that use this formula for the calculation of the number of copies, such as:

<http://cels.uri.edu/gsc/cndna.html> (from the Genomics and Sequencing Center of the University of Rhode Island)

<https://www.idtdna.com/pages/education/decoded/article/calculations-converting-from-nanograms-to-copy-number> (from Integrated DNA technologies)

<https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/dna-copy-number-calculator.html> (from Fisher)

Minor Concerns:

Materials: primers are incomplete

We have revised the materials

Reviewer #2:

Manuscript Summary:

The importance of the analysis of the microbiota in different lines of research is increasingly consolidated, but many of them do not need a deep analysis like that obtained by sequencing. The authors provide here two protocols for oral antibiotic treatment of mice and a qPCR based method to quantify antibiotic-induced changes in faecal bacteria. They may serve as a quick, cost-effective and reliable tool to manipulate the murine intestinal microbiota and to study of the effects of antibiotic treatment in intestinal homeostasis and disease.

Minor Concerns:

This is an experimental protocol, so it would be important to further detail the region for which the primers were designed. (a figure representing this region). In addition, the construction of the vector containing the 16S rRNA gene (figure)

We thank the reviewer for his/her comments and the appreciation of our manuscript.

The primers used to amplify 16S rRNA were not designed by ourselves, but obtained from an already published paper. Consequently, we have included the appropriate reference for this in the manuscript (ref 13). Also, the plasmid used for cloning is included in a commercially available kit (TOPO TA cloning). We have included this kit in the list of materials.